Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related ABT
St. Jude's Abbott Merger On Track For Q4
Barclays Says Investors Underestimate St. Jude Medical 's Potential
St. Jude Medical: A Great Short With 2.5x Risk/Reward (Seeking Alpha)
Related PCLN
Strategies For A Sleepy Bull Market
10 Biggest Price Target Changes For Thursday
Expedia Inks Red Lion Deal Amid Hilton, Marriott Booking Rivalry (Investor's Business Daily)

Analysts at Goldman Sachs upgraded Abbott Laboratories (NYSE: ABT) from “neutral” to “buy.” The target price for Abbott Laboratories has been raised from $38 to $44. Abbott's stock closed at $36.59 on Friday.

Deutsche Bank upgraded priceline.com (NASDAQ: PCLN) from “hold” to “buy.” The target price for priceline.com has been raised from $715 to $900. priceline.com's shares closed at $813.66 on Friday.

Analysts at Maxim Group upgraded J.C. Penney Company (NYSE: JCP) from “hold” to “buy.” The target price for J.C. Penney has been raised from $16.50 to $27. J.C. Penney's shares closed at $18.01 on Friday.

Morgan Stanley upgraded E-Commerce China Dangdang (NYSE: DANG) from “equal-weight” to “overweight.” The target price for E-Commerce China Dangdang has been raised from $5 to $6.50. E-Commerce China Dangdang's shares closed at $5.71 on Friday.

Latest Ratings for ABT

DateFirmActionFromTo
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy
Jun 2016Edward JonesUpgradesHoldBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (ABT + DANG)

View Comments and Join the Discussion!